OBJECTIVE: To determine the role of plasma insulin concentration in regulating glucose and lipid metabolism in insulin-resistant obese Zucker rats and to compare obese rats with lean controls with respect to changes in insulin sensitivity. DESIGN: Animal study of lean and obese rats with or without insulin sensitizer, YM268. ANIMALS: Nine week old male lean (Fa/±) and obese (fa/fa) Zucker rats. MEASUREMENTS: Plasma glucose, insulin, triglyceride (TG), non-esteri®ed fatty acid (NEFA), cholesterol at baseline and after 14 d, the dose of YM268 for exhibiting a 30% decrease in each parameter (ED 30 ). RESULTS: Insulin, TG, and NEFA concentrations were approximately 2±6 times higher in obese rats. YM268 had no effect on glucose but decreased insulin in lean and obese rats with ED 30 of 3.0 and 2.9 mg/kg. YM268 also reduced TG and NEFA in lean and obese rats [ED 30 (mg/kg): lean; 4.1 (TG), 5.0 (NEFA), obese; 2.1, 3.0]. A signi®cant correlation of either TG or NEFA level to insulin was established in lean and obese rats. CONCLUSION: Plasma TG and NEFA, but not cholesterol concentration, are dependent on plasma insulin in lean and obese Zucker rats, and insulin sensitivity with respect to TG and NEFA metabolism in obese rats may not be different from that in lean rats.
Introduction
Obesity is frequently associated with insulin resistance, decreased insulin action on stimulating glucose utilization in the peripheral tissue 1, 2 and decreased ability of insulin to reduce hepatic glucose output. 3 Insulin resistance is often accompanied by elevated concentrations of plasma insulin and abnormalities in lipid and lipoprotein metabolism, such as hypertriglyceridemia and low concentrations of high-density lipoprotein (HDL) cholesterol. 4, 5 These metabolic abnormalities may be risk factors for non-insulindependent diabetes mellitus (NIDDM) and coronary heart disease. 6, 7 Although there have been many reports showing a linkage between insulin resistance and glucose intolerance in diabetic animals, 8 Kodama et al clearly demonstrated that the linkage between them was not always observed because insulin resistance occurred before the manifestation of hyperglycemia in young db/db mice. 9 Furthermore, lipoprotein abnormalities often precede the onset of NIDDM by many years and persist despite achievement of euglycemia. NIDDM and coronary heart disease are often aggravated by the multiple effects of abnormalities in glucose and lipid metabolism.
Several insulin sensitizers are reported to ameliorate insulin resistance in the genetically obese animals, such as obese Zucker rats, Wistar fatty rats, ob/ ob mice and KK mice. 10±12 Unlike other known hypoglycemic agent such as sulfonylureas, insulin sensitizers do not stimulate insulin secretion from the pancreas. 10 One of the thiazolidinedione derivatives, pioglitazone, decreased hyperglycemia, hyperinsulinemia, and lipids abnormalities in obese Zucker rats, KKA y mice and Wistar fatty rats. 11, 13, 14 This agent, however, had no effect on blood glucose concentrations in the corresponding lean littermates whereas plasma insulin levels were signi®cantly lowered. 11, 14 Although the mechanisms by which thiazolidinedione derivatives improve insulin resistance are not entirely understood, a wide variety of mechanisms has so far been proposed. Pioglitazone was reported to ameliorate insulin resistance by increasing insulinstimulated autophosphorylation of insulin receptor and its kinase activity, 15 whereas this agent caused no increases in autophosphorylation and kinase activity of the receptor in the corresponding lean littermates. Under the same conditions, plasma insulin and triglyceride (TG) concentrations were signi®cantly decreased by this agent although plasma glucose concentration remained unchanged. These ®ndings with insulin sensitizers may not indicate that such changes in insulin and lipid metabolism in normoglycemic rats are through insulin receptor kinase activity and/or improved glycemic control.
To further elucidate the mechanism of insulin resistance, we have determined the role of plasma insulin in regulating glucose and lipid metabolism in lean and obese Zucker rats and have compared obese rats with lean controls with respect to insulin sensitivity. Lean and obese Zucker rats were treated with or without YM268, a thiazolidinedione derivative, for 14 d. The dose of YM268 required to cause a 30% decrease in insulin, TG, or non-esteri®ed fatty acid (NEFA) concentrations (ED 30 ) in these animals was obtained using dose-response curves based on least squares ®tting method. The ED 30 values were used to compare insulin sensitivity with respect to glucose and lipid metabolism in lean and obese rats.
Methods

Materials
YM268, bis {4-[(2,4-dioxo-5-thiazolidinyl) methyl]-phenyl} methane ( Figure 1 ) was synthesized at Yamanouchi Pharmaceutical Co., Ltd. (Tsukuba, Japan). All other reagents were of analytical grade commercially available.
Animals
Male KK mice were purchased from CLEA Japan (Tokyo, Japan) and housed in individual cages and fed on moderately high-calorie laboratory chow (CMF, 373 kcal/100 g, Oriental Yeast Industry, Tokyo, Japan). KK mice, more than 40 g of body weight, were used in this study. Male obese (fa/fa) Zucker rats and their lean littermates (Fa/±) at seven weeks of age were obtained from Charles River Laboratories (Wilmington, MA, USA) and allowed free access to laboratory chow (CE-2, 341 kcal/100 g, CLEA Japan, Tokyo, Japan). The animals were kept in a 12 : 12 h light-dark cycle.
Experimental design
Male KK mice showing blood glucose levels of more than 11 mmol/l were dosed with YM268, or vehicle orally once a day for 4 d. Doses of this agent were 1, 3, and 10 mg/kg. The hypoglycemic activity was evaluated by blood glucose concentration in the fed state 16 h after the last dosing. Obese Zucker rats at nine weeks of age were orally given YM268, suspended in 0.5% methylcellulose, at doses of 1, 3, 10, and 30 mg/kg for 14 d. The corresponding lean rats also received the same drug regimen, except the lowest dose (1 mg/kg) was omitted. On day 11 after overnight fasting, glucose tolerance and insulin secretion were evaluated with the use of a 3-h oral glucose tolerance test. The 40% glucose solution (5 ml/kg) was given orally, and blood samples for the determination of blood levels of glucose and insulin were drawn from the tip of the tail vein with heparinized haematocrit tubes at 0, 30, 60, 120, and 180 min. The effects of YM268 on glucose or insulin concentration after glucose load were evaluated by the product of glucose or insulin concentration by time interval (the area under courve of glucose or insulin). On day 15 from the start of drug treatment, all Zucker rats in the fed state were bled for the determination of blood glucose, insulin, TG, NEFA, cholesterol, and HDLcholesterol concentrations. In order to obtain ED 30 value of YM268 for insulin, TG, or NEFA in lean or obese Zucker rats, the logarithm of the dose of YM268 vs plasma concentration of each parameter was linearized by least-squares ®tting (SAS Software, Tokyo, SAS Institute Japan). The regression equation was used to determine the ED 30 . The experimental protocol was approved by the local animal ethics committee for animal studies.
Analytical procedures
Blood glucose was analyzed by glucose oxidase method (Glucose mono test, Boehringer Mannheim, Tokyo, Japan) and insulin was determined with radioimmunoassay (Incstar, Stillwater, MN, USA) using rat insulin as a standard. The intra-or inter-assay variation for immunoassay for insulin was 6.4 or 8.5% when 12.5 ng/ml of insulin was used. NEFA and TG concentrations were determined by colorimetric assays with kits purchased from Wako Pure Chemicals (Osaka, Japan), and cholesterol concentration was determined with a kit purchased from Boehringer Mannheim (Cholesterol mono test, Tokyo, Japan) and HDL-cholesterol was determined after precipitation of low density lipoprotein (LDL) and very low density lipoprotein (VLDL) by heparin and Mn . 16 In this study LDL-cholesterol level was de®ned as follows: LDL-cholesterol (cholesterol) ± (HDL-cholesterol).
Statistical analysis
Data are given as the mean AE SEM. Comparisons between experimental groups were made using oneway ANOVA followed by any one of Dunnett's multiple range test, Sheffe-S-method and Newman± Keuls multiple range test. Differences were accepted as signi®cant at the P`0.05 level. Oral administration of multiple doses of YM268 to spontaneously diabetic, fed KK mice for 4 d resulted in a dose-dependent fall in blood glucose concentration ( Figure 2 ). The estimated dose of YM268 for exhibiting a 30% decrease in blood glucose concentration from the pre-treatment level (ED 30 ) was 3.6 mg/kg.
Effects of YM268 on concentrations of blood glucose and plasma insulin in lean and obese Zucker rats
Concentrations of blood glucose and plasma insulin in the fed state were measured in nine-week-old lean and obese Zucker rats treated with or without the different doses of YM268 for 4 or 14 d (Figure 3 and 4) . YM268 failed to lower blood glucose concentrations signi®cantly in any groups, although blood glucose concentration was not signi®cantly elevated in obese rats. On the other hand, YM268 showed a signi®cant dose-dependent decrease in plasma insulin concentration in both lean and obese Zucker rats. During the course of a 14 d treatment, YM268 had no effect on body weight in lean and obese Zucker rats (data not shown).
Effects of YM268 on glucose and insulin concentrations after oral glucose tolerance in lean and obese Zucker rats A signi®cant reduction in both glucose and insulin concentrations after a glucose load was observed in fasted lean and obese rats treated with YM268 (Table  1) . However, the magnitude of reduction in insulin In order to clarify the relationship between plasma insulin concentration and lipid metabolism, plasma TG and NEFA concentrations were determined in lean and obese Zucker rats treated with or without YM268. As shown in Table 2 , plasma insulin, TG, and NEFA levels were 2.3±5.6 times higher in obese rats. YM268 administered for 14 d showed a signi®cant dosedependent decrease in plasma insulin levels with ED 30 values of 3.0 mg/kg for lean rats and 2.9 mg/ kg for obese rats, respectively. Similarly, YM268 lowered TG and NEFA concentrations in lean and obese Zucker rats in a dose-dependent manner. The ED 30 of YM268 for lowering TG or NEFA concentration was not altered between lean and obese groups and was closely related to the respective ED 30 for lowering plasma insulin concentration. These ®ndings may indicate that the plasma TG and NEFA concentrations are solely regulated by plasma insulin concentration in lean and obese Zucker rats. This was con®rmed by the existence of a signi®cant correlation between plasma insulin concentration and either TG or NEFA concentration in lean and obese animals ( Figure 5 ).
Plasma cholesterol concentrations in YM268-treated lean and obese Zucker rats
Neither total cholesterol nor HDL-cholesterol concentration was signi®cantly changed by the administration of YM268 to lean or obese Zucker rats for 14 d (Figure 6 ). In addition, the effects of YM268 on LDLcholesterol concentrations were inconsistent in lean and obese rats. As shown in Figure 7 , however, a signi®cant correlation between HDL-cholesterol and LDL-cholesterol concentrations was observed in obese Zucker rats, but not in lean Zucker rats, indicating that LDL-and HDL-cholesterol metabolism was not solely dependent on plasma insulin concentration.
Discussion
Obesity is frequently associated with compensatory hyperinsulinemia due to the decreased glucose uptake in the peripheral tissue 17, 18 and decreased ability of insulin to reduce hepatic glucose output. 3 Hyperinsulinemia is often accompanied by abnormalities in 19, 20 This metabolically abnormal state may be one of the most important risk factors for coronary heart disease. 6, 7, 21 In this study we have examined the role of plasma insulin in regulating glucose and lipid metabolism in obese Zucker rats with a marked hyperinsulinemia and their lean littermates showing normal insulin level. The sensitivity of glucose and lipid metabolism in response to plasma insulin concentration in lean and obese Zucker rats was evaluated by the doses of YM268, a thiazolidinedione derivative, for exhibiting a 30% reduction in each parameter.
The administration of YM268 to diabetic KK mice for 4 d resulted in a marked fall in blood glucose concentration in a dose dependent manner (Figure 2) . The ED 30 value of YM268 for lowering blood glucose was 3.6 mg/kg. Troglitazone, pioglitazone, englitazone, and BRL 49653 were also reported to be effective in this or other insulin-resistant mouse models.
10±12,22 YM268 failed to decrease blood glucose concentration signi®cantly in lean and obese Zucker rats, although blood glucose concentration was not signi®cantly elevated in these obese rats (Figure 3 ). This agent, however, dose-dependently reduced plasma insulin concentration not only in obese Zucker rats, but also in lean controls ( Figure  4) . The similar effect of YM268 on plasma insulin levels was observed in Table 1 , where YM268 improved glucose tolerance and normalized insulin secretion after a glucose load in lean and obese Zucker Table 2 . Linear lines were drawn by leastsquares ®tting method, A: f(x) 8.95x 4.60, r 0.951, P`0.01, B: f(x) 9.09x 0.15, r 0.935, P`0.01.
Insulin sensitizer and lipid metabolism O Noshiro et al rats. These ®ndings are compatible with several reports from other laboratories, 11, 14, 19 but are incompatible with the ®ndings made by de Souza et al 23 who did not observe a decline in insulin concentration in pioglitazone-treated normal rats. It is not known the reason why this difference occured but there is a possibility that the ability of insulin sensitizers to decrease insulin concentration in lean rats is dependent on the initial insulin levels which may be proportional to the degree of insulin resistance present in lean animals.
It is unlikely that the effect of YM268 on plasma insulin levels in lean and obese rats may be secondary to the reduction in food intake because YM268 had no effect on body weight in these animals during the course of the experiments (data not shown). Bowen et al 19 studied lean and obese Zucker rats and found that the treatment with englitazone signi®cantly reduced insulin concentration in fasted lean and obese rats. Pioglitazone also reduced insulin levels in Wistar fatty rats and the corresponding lean controls. 11 Recently, Masuda et al. 24 reported the interesting observations that troglitazone enhanced glucose-or glibenclamideinduced insulin secretion from pancreatic beta cells in vitro at a low concentration but inhibited it at a high concentration. This agent showed a high af®nity to the sulfonylurea receptor but had no effect on K ATP channels. On the other hand, pioglitazone did not show any effect on glucose-stimulated insulin secretory responses of islets isolated from normal rats. 23 Although there has been no data about the effect of YM268 on insulin secretion in vitro, our preliminary ®ndings indicated that it had no acute effect on plasma insulin levels after a single administration in rats (data not shown). Therefore, it is unlikely that the YM268 as well as other insulin sensitizers reduced plasma insulin concentration through the reduction of food intake or through the direct inhibition of insulin secretion from the pancreas.
In order to clarify the difference in insulin sensitivity to lipid metabolism between lean and obese animals, plasma levels of TG and NEFA were determined in lean and obese Zucker rats treated with or without YM268. Plasma insulin, TG, and NEFA levels in the obese rats were severalfold higher compared to lean controls. YM268 dose-dependently decreased insulin concentration with the ED 30 values of 3.0 mg/kg for lean rats and 2.9 mg/kg for obese rats ( Table 2) . One of the most interesting ®ndings in this study is that YM268 dose-dependently lowered TG and NEFA concentrations not only in obese rats, but also in lean rats. In addition, the ED 30 of YM268 for lowering either TG or NEFA concentration in obese rats was very close to that in lean controls, and then was closely related to the ED 30 for lowering plasma insulin concentration. These observations are supported by the evidence that there is a signi®cant positive correlation of either plasma TG or NEFA to plasma insulin ( Figure 5 ). Based on these observations, we should point out two key ®ndings. First, the reduction in insulin, TG, and NEFA by YM268 is not secondary to the reduction in blood glucose. Second, the main cause for the abnormalities concerning TG and NEFA metabolism in obese Zucker rats are not the attenuated insulin sensitivity to lipid metabolism, but the increased pool size of these metabolites. Therefore, it is highly possible that these lipid abnormalities are reversed by appropriate dietary or pharmacological therapy which reduces the intake or the production of TG and NEFA.
Although the mechanism by which YM268 improves lipid metabolism remains to be fully elucidated in this study, plasma NEFA concentration is known to be one of the factors causing insulin resistance. 25 A glucose-fatty acid cycle in muscle has been known for many years. 26 The oxidation of NEFA decreases glucose uptake and utilization through substrate competition. Clo®brate or acipimox, which decreases plasma NEFA concentration, improves glucose tolerance or insulin sensitivity in NIDDM patients. 27, 28 Therefore, there is a possibility that the reduction in NEFA by YM268 is the driving force for the metabolic changes observed in this study. Further work will be necessary to examine this possibility.
In summary, plasma TG and NEFA, but not cholesterol concentration, were dependent on plasma insulin concentration in lean and obese Zucker rats. Insulin sensitivity with respect to TG and NEFA metabolism in obese rats was not different from that in lean rats, indicating that lipid abnormalities in obese Zucker rats are due to the increased pool size of the lipids.
